Latest Breaking News On - Nextar chempharma solutions - Page 1 : vimarsana.com

MindMed Announces Launch of Collaboration with Nextage Therapeutics Brain Targeting Liposome System News provided by Share this article Share this article NEW YORK, May 24, 2021 /PRNewswire/ MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading clinical stage psychedelic medicine company, and Nextage Therapeutics (TASE: NXTG), an Israeli innovative drug development company, announce the execution of a Memorandum of Understanding (the MOU ) regarding the launch of an exclusive collaborative development program to optimize the delivery of certain psychedelic drug candidates, leveraging Nextage s proprietary Brain Targeting Liposome System (BTLS) delivery technology, for which it has an exclusive license.  MindMed and Nextage will initially collaborate to optimize the delivery of drug products based on noribogaine, and ultimately other ibogaine derivatives, and will share development costs and intellectual property arising from the collaboration.

Abraham dreazenMiri halperin wernliExchange commissionMedicine mindmed incNextar chempharma solutionsPilot programTeva pharmaceuticalsNextage therapeuticsBrain targeting liposome systemBlood brainMed executive presidentBlood brain barrierIsrael makovMind medicine mindmed incமீறி ஹால்பெரின் வெற்ணிலிபரிமாற்றம் தரகு